CAMBRIDGE, MA / ACCESSWIRE / May 22, 2024 / Archetype Therapeutics, an AI-native company pioneering the integrative use of generative chemogenomics in drug discovery, announced today that it has discovered compounds for the treatment of early-stage lung adenocarcinoma (esLUAD) by screening billions of compounds from the Enamine REAL Space chemical library and other libraries. These pre-lead drugs are being validated in vitro and in vivo through Archetype-sponsored research conducted at the Icahn School of Medicine at Mount Sinai in the laboratory of Charles A. Powell, MD, MBA, Florette and Ernst Rosenfeld and Joseph Solomon Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Chief of the Catherine and Henry J. Gaisman Division of Pulmonary, Critical Care and Sleep Medicine for the Mount Sinai Health System in New York City.
This accomplishment was made possible by Archetype's innovations using deep learning algorithms to enable generative chemogenomics, which learns relationships between drug structures and biological changes to generate the expected biological changes that will be induced by new drugs. Archetype connects its generative chemogenomics models to orthogonal models to predict patient outcomes built from clinicogenomically-defined patient cohorts with unmet medical need. These models are used together to rapidly screen potential drugs to determine which treatments are most likely to improve patient outcomes. The drugs for screening come from libraries such as the Enamine REAL Space, comprised of approximately 38 billion make-on-demand compounds, which is reported to be the world's largest chemical library of highly synthesizable molecules. The massive screen generated and assessed more than 5 trillion gene-drug-concentration triplets.
"Our platform constitutes a fundamental advance in the rapid and massively scalable harmonization of chemistry, biology, and patient clinical outcomes in drug discovery," said Tom Neyarapally, CEO and Co-Founder of Archetype. "Other AI drug discovery efforts have focused on challenges such as designing the perfect drug structure to bind a target or identifying a potential drug's likely target. We are pioneering the use of generative chemogenomics as a force multiplier to virtually screen drugs in genomically-defined patient groups - providing early insight regarding the potential drugs' impact in patients with unmet need."
The patent-pending Archetype platform screens over 3 billion drug-like molecules a day for their effect on disease biology and how these effects impact clinical outcomes. This approach provides several advantages, including: an immediate readout to assess the expected clinical impact for each molecule screened, a built-in translational biomarker program for the discovered drugs, repurposing opportunities for safe drugs, and enormous time and cost savings in wet lab screening - including in avoidable animal testing.
The most promising esLUAD drugs discovered by Archetype are being validated using in vitro and in vivo experimental protocols designed in Dr. Powell's lab at Icahn Mount Sinai. The protocols were utilized in work published by Dr. Powell and colleagues in Nature Communications in 2022 to repurpose drugs into esLUAD. "Lung cancer remains the leading cause of cancer death worldwide," said Dr. Powell. "Our recently published work demonstrated our experimental protocol's ability to identify repurposed drugs that can intercept lung cancer at early stages for the roughly half of such patients for whom there are no established drug targets. Our team is excited to now apply our proven protocol to the molecular candidates discovered by Archetype from billions of drug-like molecules to enable the rapid development of new drugs for these patients with unmet need."
About Archetype
Archetype Therapeutics is an AI-native biotech founded by genomic data science veterans and working with clinician leaders and scientific experts. Archetype is pioneering the use of AI for generative chemogenomics - enabling the virtual screening of billions of potential drugs against patient clinical outcomes per day. The disease-agnostic Archetype platform has been deployed in metastatic castration-resistant prostate cancer (mCRPC), early-stage lung adenocarcinoma (esLUAD), metastatic melanoma, and idiopathic pulmonary fibrosis (IPF), and has accurately predicted the outcomes of clinical trials and the impact of drugs in these diseases. Archetype is partnering across the healthcare and life sciences ecosystem to rapidly discover and develop patient-driven therapeutics.
Please contact Tom Neyarapally at tom@archetypetx.com to discuss how to partner with us on our mission to rapidly discover and develop therapies for underserved patients.
SOURCE: Archetype Therapeutics
View the original press release on accesswire.com
